S. V. Kuzmicheva

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

E. Zueva, L. Bolotina, D. Stroyakovskiy, 2021 .

Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience

I. Poddubnaya, I. V. Kolyadina, I. Ganshina, 2020 .